tilS Antibody

What are the primary antibody markers used to characterize different TIL populations?

Different TIL populations require specific antibody panels for comprehensive characterization based on their lineage and function. The following antibody markers are commonly employed:

For functional characterization, researchers should incorporate additional markers such as PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT for exhaustion assessment, as well as granzyme B and perforin for cytotoxic potential evaluation. Antibody titration is critical, with each requiring optimization to minimize background and maximize signal specificity .

How do researchers isolate and expand TILs from tumor samples?

TIL isolation and expansion from tumor samples involves a multi-step approach that has evolved significantly in recent years:

Initial isolation typically employs either mechanical dissociation (tumor tissue cut into small fragments of 1-3 mm³) or enzymatic digestion (using collagenase, DNase, and/or hyaluronidase) to create single-cell suspensions. Following density gradient centrifugation using Ficoll or Percoll to separate lymphocytes, researchers may employ magnetic separation or flow sorting using antibodies against lymphocyte markers for further purification .

Expansion protocols generally follow one of two approaches:

• Fragment culture method: Small tumor fragments are cultured directly with high-dose IL-2 (typically 6,000 IU/mL)

• Pre-rapid expansion protocol (pre-REP): Initial expansion with IL-2 for 10-14 days, followed by REP using anti-CD3 antibodies and irradiated feeder cells for an additional 14 days

Modern protocols have incorporated important improvements such as:

• Addition of CD137 (4-1BB) agonistic antibodies during culture to preferentially expand tumor-reactive T cells

• Use of CD3/CD28 activator beads as an alternative to anti-CD137 agonist antibodies

• Culture in gas-permeable flasks to improve nutrient access

The typical expansion period ranges from 4-8 weeks, yielding 10-150 billion TILs from a single tumor fragment, sufficient for clinical applications .

What role do anti-CD3 antibodies play in TIL activation and expansion?

Anti-CD3 antibodies serve as crucial reagents in TIL activation through several mechanisms:

The primary activation mechanism involves binding to the CD3 complex associated with the T cell receptor (TCR), triggering intracellular signaling cascades that promote T cell activation, proliferation, and effector functions. When used in solid-phase (plate-bound or bead-bound), anti-CD3 antibodies provide stronger and more sustained activation than soluble antibodies .

Methodological applications include:

• Initial TIL expansion: Solid-phase anti-CD3 antibodies can be more effective than high concentrations of IL-2 for expanding TILs when used at the start of culture

• Reactivation of exhausted TILs: TILs that become refractory to IL-2-induced expansion can be reactivated using anti-CD3 antibodies

• Rapid expansion protocol (REP): Anti-CD3 antibodies (typically the OKT3 clone) are used in combination with irradiated feeder cells to achieve massive expansion

Research has demonstrated that anti-CD3 activation can restore the function of TILs that have become refractory to IL-2, making it a valuable tool in both research and therapeutic development .

How can researchers assess TIL exhaustion in the tumor microenvironment?

TIL exhaustion represents a state of progressive loss of effector function due to chronic antigen stimulation and immunosuppressive signals. Antibody-based assessment approaches include:

Key exhaustion markers detectable by antibodies include:

• PD-1 (programmed cell death protein 1): Primary exhaustion marker

• CTLA-4 (cytotoxic T-lymphocyte-associated protein 4): Co-inhibitory receptor

• TIM-3 (T-cell immunoglobulin and mucin-domain containing-3): Associated with severe exhaustion

• LAG-3 (lymphocyte-activation gene 3): Inhibitory receptor

• TIGIT (T cell immunoreceptor with Ig and ITIM domains): Associated with dysfunctional TILs

Methodological approaches include:

• Flow cytometry: Multi-parameter analysis allows simultaneous detection of multiple exhaustion markers

  • Co-expression analysis is particularly valuable as TIM-3+PD-1+ TILs show greater dysfunction than PD-1+ only TILs

• Functional assessment: Combining exhaustion marker antibodies with functional assays

  • Intracellular cytokine staining for IFN-γ, TNF-α, and IL-2 production

  • Proliferation assays using Ki-67 antibody

  • Cytotoxicity assessment via CD107a mobilization or granzyme B/perforin expression

Research has shown that TIGIT+CD8+ T cells typically co-express PD-1, and combined blockade of these pathways synergistically boosts CD8+ T cell effector function, resulting in enhanced tumor clearance in experimental models .

How can multiplexed antibody panels be designed for comprehensive TIL characterization?

Designing multiplexed antibody panels for robust TIL characterization requires strategic planning to maximize information while addressing technical limitations:

Panel design principles should include:

• Target selection based on research objectives:

  • Lineage markers (CD3, CD4, CD8, CD19, CD56)

  • Functional markers (cytokines, cytotoxic molecules)

  • Activation/exhaustion markers (PD-1, CTLA-4, LAG-3, TIM-3)

  • Transcription factors (T-bet, EOMES, TOX, FoxP3)

  • Tissue residency markers (CD69, CD103, CD49a)

• Technical considerations:

  • Fluorophore brightness matching to target abundance

  • Spectral overlap minimization through fluorophore selection

  • Antibody clone selection based on performance in specific applications

Methodological approaches include:

• Spectral flow cytometry (up to 30+ colors) with carefully designed panels

• Mass cytometry (CyTOF) using metal isotope-tagged antibodies to eliminate spectral overlap issues

• Multiplexed immunohistochemistry techniques including cyclic immunofluorescence and CO-Detection by indEXing (CODEX)

Validation strategies should incorporate known positive and negative controls, biological replicates, and comparison with established methods to ensure reproducibility and accuracy.

What are the methodological considerations for studying PD-1/PD-L1 expression on TILs?

Studying PD-1/PD-L1 expression on TILs requires specific methodological considerations to ensure accurate results:

Pre-analytical factors include:

• Sample handling and preservation:

  • Fresh samples preserve epitope integrity but have limited availability

  • Cryopreserved samples maintain most epitopes but require careful freezing/thawing protocols

  • Timing matters: PD-1/PD-L1 expression can change rapidly ex vivo

• Antibody selection is critical:

  • For PD-1: EH12.2H7, J116, MIH4 clones perform well in flow cytometry

  • For PD-L1: 29E.2A3, MIH1, 22C3 clones are commonly used

  • Different clones may recognize different epitopes, affecting detection sensitivity

Technical considerations include:

• Flow cytometry protocols should:

  • Perform surface staining before any intracellular staining

  • Include viability dye and lineage markers

  • Implement careful compensation, especially with dim markers

• Analytical approaches should:

  • Report PD-1/PD-L1 as both percentage positive cells and median fluorescence intensity

  • Consider PD-1 expression as a continuous rather than binary variable

  • Correlate PD-1 expression with functional assays

Researchers should be aware that therapeutic antibodies may interfere with detection antibodies through epitope masking, and that PD-1/PD-L1 expression is dynamic and influenced by cytokines, hypoxia, and treatment conditions .

How are antibody-secreting TILs engineered and what advantages do they offer?

Engineering antibody-secreting TILs represents an advanced approach to enhance immunotherapy efficacy:

Generation methodology typically involves:

• Standard TIL isolation and initial expansion with IL-2

• Genetic modification using viral vectors (lentivirus, retrovirus) for stable integration

• Engineering strategies focused on:

  • Full antibody expression with heavy and light chain genes

  • scFv (single-chain variable fragment) secretion for simpler expression

  • Fusion proteins linking scFv to cytokines or co-stimulatory ligands

• Common targets include checkpoint pathways:

  • PD-1/PD-L1 axis: Most widely studied due to established clinical efficacy

  • CTLA-4, LAG-3, TIM-3, TIGIT: Emerging targets for combination approaches

Advantages of this approach include:

• Localized checkpoint blockade:

  • Reduces systemic toxicity compared to systemic antibody administration

  • Achieves higher concentration of antibody specifically at tumor sites

• Dual mechanism of action:

  • Direct cytotoxicity through TCR recognition of tumor antigens

  • Antibody-mediated neutralization of inhibitory pathways

  • Enhancement of endogenous TIL function (bystander effect)

Early clinical results are promising, with first-in-human studies showing feasibility and preliminary safety. A clinical trial using PD1-antibody-secreting TILs in recurrent glioblastoma demonstrated encouraging efficacy with a disease control rate of 43% and 1-year survival rate of 86% .

How does the complement system interact with TILs in tumor microenvironments?

Recent research has uncovered surprising roles for the complement system in regulating TIL function:

While traditionally considered part of innate immunity, complement components like anaphylatoxins C3a and C5a can be produced by T cells and other immune effector cells. These anaphylatoxins interact with their receptors (C3aR/C5aR) expressed on T cells, with unexpected effects on anti-tumor immunity .

Research from Wang and colleagues revealed:

• The complement pathway is highly enriched in certain TIL subsets

• Complement C3-deficient mice show enhanced T-cell-mediated antitumor immune responses

• C3aR and C5aR function as a new type of coinhibitory receptor on CD8+ TILs

Mechanistically, complement activation within the tumor microenvironment can inhibit CD8+ TIL function through:

• Activation of specific signaling pathways that suppress T cell effector function

• Interference with metabolic pathways necessary for optimal T cell activity

• Modulation of the AKT pathway, affecting T cell function

What is the current status of TIL therapy in cancer treatment?

TIL therapy has emerged as a promising approach for treating solid tumors, with significant clinical development in recent years:

In melanoma, TIL therapy has shown remarkable efficacy:

Beyond melanoma, TIL therapy has shown promise in:

The standard TIL therapy protocol involves:

• Lymphodepletion via chemotherapy (typically cyclophosphamide and fludarabine)

• Infusion of 10-150 billion expanded TILs

• High-dose IL-2 administration to support TIL survival and function

How are TILs being used as prognostic biomarkers in cancer?

TILs have emerged as important prognostic biomarkers across multiple cancer types:

In breast cancer, particularly triple-negative breast cancer (TNBC):

• TILs reflect endogenous antitumor immune response and are associated with outcomes across various treatment settings

• The International TILs Working Group recommends assessment of stromal TILs (sTILs) over intratumoral TILs (iTILs) due to higher reproducibility

• High TIL density is associated with improved outcomes in TNBC, which is the most immunogenic breast cancer subtype

Methodological considerations for TIL assessment include:

• Standardized quantification methods

• Spatial distribution analysis

• Phenotypic characterization of TIL subpopulations

• Integration with other biomarkers

Ongoing clinical trials are investigating the potential role of sTILs for treatment de-escalation strategies in early-stage TNBC, potentially sparing patients from unnecessary chemotherapy based on TIL levels .

What methodological approaches are used to overcome TIL exhaustion in the tumor microenvironment?

Overcoming TIL exhaustion represents a major focus in cancer immunotherapy research, with several antibody-based strategies:

Checkpoint inhibitor antibodies:

• Anti-PD-1/PD-L1: Blocking this pathway can reinvigorate exhausted TILs

• Anti-CTLA-4: Works through distinct mechanisms to enhance T cell activation

• Combined blockade: Dual targeting of PD-1 and CTLA-4 has shown synergistic effects in clinical settings

Emerging targets include:

• Anti-TIM-3: Studies show TIM-3+PD-1+ TILs represent a highly exhausted subset, and dual blockade of PD-1 and TIM-3 can restore anti-tumor function

• Anti-TIGIT: In melanoma patients, TIGIT+CD8+ T cells co-express PD-1, and combined blockade promotes T cell proliferation and cytokine production

• Complement receptor antagonists: Blocking C3aR/C5aR shows synergy with PD-1 blockade in experimental models

Advanced engineering approaches:

• TILs engineered to secrete checkpoint inhibitor antibodies can provide localized blockade

• This approach reduces systemic toxicity while maintaining efficacy

• Clinical trials with PD1-antibody-secreting TILs have shown encouraging results in glioblastoma patients

Metabolic interventions are also being explored, as both PD-1 and CTLA-4 inhibit the activity of Akt, a crucial molecule in regulating glucose metabolism of T cells. Strategies to enhance metabolic fitness may complement antibody-based approaches to reverse exhaustion .

How can spatial distribution of TILs be analyzed using antibody-based imaging techniques?

Spatial distribution analysis of TILs provides critical information about immune-tumor interactions beyond simple quantification:

Advanced antibody-based imaging techniques include:

• Multiplexed Immunohistochemistry (mIHC) and Immunofluorescence (mIF):

  • Sequential staining with multiple primary antibodies, secondary antibodies, and chromogens/fluorophores

  • Multispectral imaging and unmixing algorithms to separate overlapping spectra

  • Cell segmentation based on nuclear and membrane markers

  • Spatial relationship analysis between different cell types

• Imaging Mass Cytometry (IMC) and Multiplexed Ion Beam Imaging (MIBI):

  • Metal-tagged antibodies allowing simultaneous detection of 40+ targets

  • Laser ablation or ion beam to release metal tags for mass spectrometry detection

  • High-dimensional spatial analysis with single-cell resolution

Spatial analysis metrics include:

• Cell density measurements across different regions (tumor center, invasive margin, stroma)

• Proximity analysis measuring distances between different cell types

• Cell clustering and neighborhood analysis

• Tumor-immune architecture classification:

  • Immune exclusion: TILs restricted to tumor periphery

  • Immune desert: Few TILs present

  • Inflamed: TILs throughout tumor parenchyma

Clinical correlations demonstrate that TIL spatial patterns, particularly the proximity of CD8+ T cells to tumor cells, predict immunotherapy efficacy better than simple TIL quantification, highlighting the importance of these advanced spatial analysis techniques .

What are the latest approaches for expanding TILs when anti-CD137 agonist antibodies are unavailable?

The discontinued supply of GMP-grade anti-CD137 agonist has prompted researchers to develop alternative approaches for TIL expansion:

A recently developed GMP-adherent protocol uses IL-2 and T-cell activator CD3/CD28 without anti-CD137 agonist to expand TILs in a clinically feasible manner:

• The procedure involves:

  • Collection of resected tumors and cutting tissues into fragments

  • Expansion of non-selected TILs using IL-2 and CD3/CD28 activator over 2-3 weeks

  • Rapid expansion for an additional 2 weeks

• Validation results show:

  • Successful expansion in >90% of collected samples

  • Preferential increase in CD8+ T cells

  • Demonstrated anti-tumor activity with 37.5% reduction in autologous tumor cells within 24 hours

  • Strong inhibition of liposarcoma growth in autologous patient-derived xenograft models

This approach has received FDA approval for clinical trial use (IND 30562), demonstrating its feasibility for therapeutic applications. The method offers a crucial alternative given the challenges in obtaining anti-CD137 agonist antibodies for clinical manufacturing .

What quality control measures are essential for TIL production in research settings?

Quality control is critical for ensuring consistent and reliable TIL products for research applications:

Key quality control measures include:

• Sterility testing:

  • Cultures must be regularly monitored for bacterial, fungal, and mycoplasma contamination

  • Standardized sterility tests should be performed at multiple timepoints during expansion

• Phenotypic characterization:

  • Flow cytometry to assess T cell subsets (CD3+, CD4+, CD8+)

  • Evaluation of memory phenotype (naïve, central memory, effector memory)

  • Assessment of exhaustion markers (PD-1, TIM-3, LAG-3)

• Functional validation:

  • Cytokine production capacity (IFN-γ, TNF-α, IL-2)

  • Cytotoxicity against autologous tumor cells

  • Proliferative capacity in response to stimulation

• Tumor specificity assessment:

  • Detection of residual tumor cells using immunohistochemical staining for tumor markers

  • Flow cytometry evaluation of tumor markers

  • Functional assays against autologous and allogeneic targets

• Expansion metrics:

  • Cell yield relative to starting material

  • Expansion rate and doubling time

  • Viability measurements throughout culture period

For highest quality, researchers should implement detailed standard operating procedures (SOPs) covering all aspects from tumor processing through final product characterization, with particular attention to maintaining GMP-like conditions even in research settings .

How are engineered TILs advancing beyond traditional adoptive cell therapy approaches?

Engineered TILs represent the next frontier in adoptive cell therapy, incorporating advanced modifications to enhance efficacy:

Novel engineering approaches include:

• Checkpoint inhibitor-secreting TILs:

  • TILs engineered to secrete anti-PD-1 antibodies upon activation within the tumor microenvironment

  • First-in-human studies demonstrate feasibility and preliminary efficacy

  • Disease control rate of 43% in recurrent glioblastoma, with 86% 1-year survival rate

• Armored CAR-TILs:

  • TILs engineered with chimeric antigen receptors targeting solid tumor antigens

  • Additional modifications to secrete immune-enhancing factors

  • Example includes ROR1-targeting CAR-TILs that secrete anti-PD-1 upon activation within the tumor microenvironment

• Metabolism-enhanced TILs:

  • Engineering approaches to improve metabolic fitness in the hostile tumor microenvironment

  • Modifications targeting glycolysis, fatty acid oxidation, or mitochondrial function

  • These approaches aim to overcome metabolic exhaustion mechanisms

• Combination engineered features:

  • TILs with multiple genetic modifications addressing different aspects of tumor immunity

  • Example: TILs engineered to both express a CAR and secrete checkpoint inhibitors

  • This approach provides complementary mechanisms of action against heterogeneous tumors

Technical advancements facilitating these approaches include improved gene delivery methods, precise genome editing with CRISPR-Cas9, and enhanced manufacturing protocols that maintain TIL fitness throughout the engineering process .

The combination of natural tumor recognition through endogenous TCRs with engineered enhanced functions represents a promising direction for overcoming the limitations of current immunotherapies, particularly for solid tumors .